BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1560 related articles for article (PubMed ID: 19360080)

  • 1. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.
    Soucy TA; Smith PG; Milhollen MA; Berger AJ; Gavin JM; Adhikari S; Brownell JE; Burke KE; Cardin DP; Critchley S; Cullis CA; Doucette A; Garnsey JJ; Gaulin JL; Gershman RE; Lublinsky AR; McDonald A; Mizutani H; Narayanan U; Olhava EJ; Peluso S; Rezaei M; Sintchak MD; Talreja T; Thomas MP; Traore T; Vyskocil S; Weatherhead GS; Yu J; Zhang J; Dick LR; Claiborne CF; Rolfe M; Bolen JB; Langston SP
    Nature; 2009 Apr; 458(7239):732-6. PubMed ID: 19360080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells.
    Xu GW; Toth JI; da Silva SR; Paiva SL; Lukkarila JL; Hurren R; Maclean N; Sukhai MA; Bhattacharjee RN; Goard CA; Medeiros B; Gunning PT; Dhe-Paganon S; Petroski MD; Schimmer AD
    PLoS One; 2014; 9(4):e93530. PubMed ID: 24691136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer.
    Soucy TA; Smith PG; Rolfe M
    Clin Cancer Res; 2009 Jun; 15(12):3912-6. PubMed ID: 19509147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nedd8-Activating Enzyme Is a Druggable Host Dependency Factor of Human and Mouse Cytomegalovirus.
    Flores-Martínez YA; Le-Trilling VTK; Trilling M
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression.
    Jia L; Li H; Sun Y
    Neoplasia; 2011 Jun; 13(6):561-9. PubMed ID: 21677879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of tumor angiogenesis by targeting the protein neddylation pathway.
    Yao WT; Wu JF; Yu GY; Wang R; Wang K; Li LH; Chen P; Jiang YN; Cheng H; Lee HW; Yu J; Qi H; Yu XJ; Wang P; Chu YW; Yang M; Hua ZC; Ying HQ; Hoffman RM; Jeong LS; Jia LJ
    Cell Death Dis; 2014 Feb; 5(2):e1059. PubMed ID: 24525735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells.
    Luo Z; Pan Y; Jeong LS; Liu J; Jia L
    Autophagy; 2012 Nov; 8(11):1677-9. PubMed ID: 22874562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924.
    Liao H; Liu XJ; Blank JL; Bouck DC; Bernard H; Garcia K; Lightcap ES
    Mol Cell Proteomics; 2011 Nov; 10(11):M111.009183. PubMed ID: 21873567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantifiable analysis of cellular pathway inhibition of a Nedd8-activating enzyme inhibitor, MLN4924, using AlphaScreen.
    Yan ZH; Burkhardt A; Loke HK; Chen J; Xu Q; Brauer P; Ma J; Lin Y; Garcia K; Dick LR; Bembenek ME
    Anal Biochem; 2013 Aug; 439(2):109-15. PubMed ID: 23624319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.
    Brownell JE; Sintchak MD; Gavin JM; Liao H; Bruzzese FJ; Bump NJ; Soucy TA; Milhollen MA; Yang X; Burkhardt AL; Ma J; Loke HK; Lingaraj T; Wu D; Hamman KB; Spelman JJ; Cullis CA; Langston SP; Vyskocil S; Sells TB; Mallender WD; Visiers I; Li P; Claiborne CF; Rolfe M; Bolen JB; Dick LR
    Mol Cell; 2010 Jan; 37(1):102-11. PubMed ID: 20129059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overactivated neddylation pathway as a therapeutic target in lung cancer.
    Li L; Wang M; Yu G; Chen P; Li H; Wei D; Zhu J; Xie L; Jia H; Shi J; Li C; Yao W; Wang Y; Gao Q; Jeong LS; Lee HW; Yu J; Hu F; Mei J; Wang P; Chu Y; Qi H; Yang M; Dong Z; Sun Y; Hoffman RM; Jia L
    J Natl Cancer Inst; 2014 Jun; 106(6):dju083. PubMed ID: 24853380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.
    Swords RT; Kelly KR; Smith PG; Garnsey JJ; Mahalingam D; Medina E; Oberheu K; Padmanabhan S; O'Dwyer M; Nawrocki ST; Giles FJ; Carew JS
    Blood; 2010 May; 115(18):3796-800. PubMed ID: 20203261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy.
    Zhao Y; Morgan MA; Sun Y
    Antioxid Redox Signal; 2014 Dec; 21(17):2383-400. PubMed ID: 24410571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.
    Smith MA; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Morton CL; Wu J; Smith PG; Yu J; Houghton PJ
    Pediatr Blood Cancer; 2012 Aug; 59(2):246-53. PubMed ID: 22012946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and application of NEDD8 E1 inhibitors.
    Bruzzese FJ; Milhollen MA; Gavin JM; Josephine HR; Brownell JE
    Methods Mol Biol; 2012; 832():577-88. PubMed ID: 22350913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.
    Nawrocki ST; Griffin P; Kelly KR; Carew JS
    Expert Opin Investig Drugs; 2012 Oct; 21(10):1563-73. PubMed ID: 22799561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells.
    Lan H; Tang Z; Jin H; Sun Y
    Sci Rep; 2016 Apr; 6():24218. PubMed ID: 27063292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of glioblastoma by targeting the overactivated protein neddylation pathway.
    Hua W; Li C; Yang Z; Li L; Jiang Y; Yu G; Zhu W; Liu Z; Duan S; Chu Y; Yang M; Zhang Y; Mao Y; Jia L
    Neuro Oncol; 2015 Oct; 17(10):1333-43. PubMed ID: 25904638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
    Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
    Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.
    Blank JL; Liu XJ; Cosmopoulos K; Bouck DC; Garcia K; Bernard H; Tayber O; Hather G; Liu R; Narayanan U; Milhollen MA; Lightcap ES
    Cancer Res; 2013 Jan; 73(1):225-34. PubMed ID: 23100467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 78.